## Edgar Filing: ANI PHARMACEUTICALS INC - Form 4/A

ANI PHARM Form 4/A February 14,	ACEUTICAL	S INC									
FORN Check th if no long	<b>I 4</b> UNITEE	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							PPROVAL 3235-0287 January 31, 2005	5-0287 Iary 31,	
subject to Section 1 Form 4 o Form 5 obligation may cont <i>See</i> Instru 1(b).	6. r Filed pu <sup>ns</sup> Section 17 inue.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES       Estimated average burden hours per response       2008         Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940       0.8									
(Print or Type I	Responses)										
1. Name and Address of Reporting Person <u>*</u> Arnold Charlotte C.			2. Issuer Name <b>and</b> Ticker or Trading Symbol ANI PHARMACEUTICALS INC [ANIP]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST			3. Date of Earliest Transaction (Month/Day/Year) 07/12/2013			Director 10% Owner X Officer (give title Other (specify below) below) CFO					
Filed			Filed(Mo	4. If Amendment, Date Original Filed(Month/Day/Year) 07/16/2013			<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting Person</li> </ul>				
(City)	(State)	(Zip)	Tab	ole I - Non-J	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		ed Date, if	3. Transactic Code (Instr. 8) Code V	4. Securit nAcquired Disposed (Instr. 3, 4	ies (A) or of (D)	5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect		
Reminder: Rep	ort on a separate lir	ne for each cl	ass of sec	urities bene	Perso inform requir	ns who res nation cont red to resp nys a curre	or indirectly. spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4. 5.	6. Date Exercisable and	7. Title and Amount of	8. Price of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	TransactionNumber	• Expiration Date	Underlying Securities	Derivative

## Edgar Filing: ANI PHARMACEUTICALS INC - Form 4/A

Security (Instr. 3)	or Exercise Price of Derivative Security	any (Month/Day/Year)	Code (Instr. 8)	of Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year)		(Instr. 3 and 4)		Security (Instr. 5)
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Option to Purchase	<u>(1)</u>				(1)	(1)	Common Stock	0 (1)	

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
The forming of the state of the	Director	10% Owner	Officer	Other			
Arnold Charlotte C. C/O ANI PHARMACEUTICALS, INC. 210 MAIN STREET WEST BAUDETTE, MN 56623			CFO				
Signatures							
/s/ Paul A. Gajer, as attorney in fact	02/14/2014						
**Signature of Reporting Person	Date						

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On July 16, 2013, the reporting person filed a Form 4 in error that reported the grant of an option to purchase 266,000 shares of common stock conditioned upon shareholder approval of an amendment to the Issuer's 2008 Stock Incentive Plan to increase the number of shares

(1) sobe conditioned upon shareholder approval of an anendment to the issuer's 2008 stock incentive rian to increase the number of shares authorized for issuance under the Plan. This amendment is being filed to correct the report of the conditional grant made on July 12, 2013. The grant will be reported following such shareholder approval, if obtained.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.